-
3 weeks ago | 
pharmacytimes.com | Luke Halpern |Saad Usmani
CommentaryVideoJune 4, 2025Author(s):,Saad Usmani, MD, MBA, FACP, FASCO, explores treatment duration, patient characteristics, and toxicity profiles in transplant-ineligible patients with newly diagnosed multiple myeloma.
-
3 weeks ago | 
pharmacytimes.com | Luke Halpern |Saad Usmani
CommentaryVideoJune 2, 2025Author(s):,Saad Usmani, MD, MBA, FACP, FASCO, discusses the subgroup analysis of transplant-ineligible (TIE) patients with newly diagnosed multiple myeloma (NDMM) from the CEPHEUS trial.
-
Feb 27, 2025 | 
nature.com | Philippe Moreau |Katja Weisel |Hartmut Goldschmidt |Saad Usmani |Robert Orlowski |Nizar Bahlis | +7 more
AbstractIn the MAIA study, daratumumab plus lenalidomide and dexamethasone (D-Rd) improved progression-free survival (PFS) and overall survival (OS) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). We report updated efficacy and safety from MAIA (median follow-up, 64.5 months), including a subgroup analysis by patient age (<70, ≥70 to <75, ≥75, and ≥80 years).
-
Jan 10, 2025 | 
businessandamerica.com | Saad Usmani
Video content above is prompted by the following:Provide a brief overview of the CEPHEUS study and the expanded analysis of MRD outcomes presented at ASH 2024. What was the objective of this study? How was this study designed/what methodology was used? What additional MRD outcomes were presented? Source link
-
Jan 10, 2025 | 
ajmc.com | Saad Usmani
OpinionVideoJanuary 10, 2025Author(s):Saad Z. Usmani, MD, MBA, FACP, discusses how the definition of the transplant-ineligible population for multiple myeloma is evolving while also addressing the challenges of standardizing minimal residual disease (MRD) as a biomarker across various treatment settings and clinical trials to ensure consistent and reliable use in treatment decision-making.
-
Jan 10, 2025 | 
ajmc.com | Saad Usmani
OpinionVideoJanuary 10, 2025Author(s):Saad Z. Usmani, MD, MBA, FACP, discusses how the CEPHEUS study, presented at ASH 2024, along with its expanded analysis of minimal residual disease (MRD) outcomes, provides valuable insights into the role of MRD as a biomarker in multiple myeloma treatment, highlighting its potential to guide therapy decisions and improve patient outcomes.
-
Jan 2, 2025 | 
ajmc.com | Saad Usmani
OpinionVideoJanuary 2, 2025Author(s):Saad Z. Usmani, MD, MBA, FACP, discusses how the MajesTEC-5 study, presented at ASH 2024, demonstrates the potential of teclistamab in combination with standard therapy in the frontline setting, highlighting its safety profile and 100% minimal residual disease (MRD) negativity after cycle 3, and explores how using bispecific antibodies like teclistamab earlier in treatment could influence future options for relapsed/refractory multiple myeloma.
-
Dec 3, 2024 | 
targetedonc.com | Saad Usmani
Saad Z. Usmani, MD, MBA, FACP, FASCO, chief of the myeloma service at Memorial Sloan Kettering Cancer Center, discusses the results and potential impact from the phase 3 CEPHEUS trial (NCT03652064) of daratumumab and hyaluronidase-fihj (subcutaneous daratumumab; Darzalex Faspro) with bortezomib, lenalidomide, and dexamethasone (VRd) for the treatment of patients with newly diagnosed multiple myeloma for whom hematopoietic stem cell transplant is not planned as initial therapy.
-
Nov 15, 2024 | 
cancernetwork.com | Saad Usmani |Rafael Fonseca |Surbhi Sidana |Ajay K. Nooka
November 15, 2024By Panelists discuss effective strategies for promoting the adoption of bispecific antibodies in relapsed/refractory multiple myeloma (R/R MM) treatment, emphasizing the importance of educational initiatives, improving care transitions between academic and community settings, addressing misconceptions, and sharing key takeaways and clinical pearls for community oncologists.
-
Nov 8, 2024 | 
cancernetwork.com | Saad Usmani |Rafael Fonseca |Surbhi Sidana |Ajay K. Nooka
November 8, 2024By Panelists discuss strategies for sequencing bispecific antibodies with B-cell maturation antigen (BCMA)–targeted therapies, considering factors such as prior CAR T-cell treatment, the impact of relapse timing on treatment decisions, and approaches for managing high-risk cytogenetics and extramedullary disease in relapsed/refractory multiple myeloma (R/R MM).
